Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$6.83 USD
+0.37 (5.73%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $6.84 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Brokerage Reports
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 1001 - 1020 ( 1022 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of July 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q1:12 Cash Burn Higher Than Expected, We Continue to View Large Financing as Inevitable
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Downgrading to UNDERPERFORM; Updated Launch Expenses Leads to Significant Anticipated Funding Gap
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Acquires Rights to BNC210 - A Potential Blockbuster for Anxiety and Depression
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partner Almirall Submits MAA in the EU for Linaclotide, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q2:11 EPS Uneventful, Next Up Is EU Linaclotide Submission
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
August 2011 Potential Milestones & Key Events - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage of Ironwood with a Hold rating
Provider: DUNCAN-WILLIAMS, INC.
Analyst: RIVKIND I
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q4 EPS a Non-Event, Linaclotide NDA Filing on Track for Q3:11
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Announces Positive Phase III results for Linaclotide in Patients with IBS with Constipation
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Announces Positive Phase III Results for Linaclotide in Patients with IBS with Constipation
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G